Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:18:44 2024-04-16 pm EDT			5-day change	1st Jan Change
39.37 ^USD	-0.76%		-6.19%	-12.07%

12:47pm	QIAGEN NV : Deutsche Bank reiterates its Buy rating	ZD
Apr. 03	Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	CI

QIAGEN N.V.: Release of a capital market information

August 05, 2020 at 06:35 am EDT

DGAP Post-admission Duties announcement: QIAGEN N.V. / Form 6-K for the quaterly period ended June 30, 2020
QIAGEN N.V.: Release of a capital market information

05.08.2020 / 12:30
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

QIAGEN N.V. hereby announces that the FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2020, was filed with the UNITED STATES SECURITIES AND EXCHANGE COMMISSION (SEC).

The document is now available on the website of QIAGEN:
https://corporate.qiagen.com/investor-relations/financial-reports#docs_o=Report%20Release%20Date,Descending&docs_Report%20Release%20Date

05.08.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	QIAGEN N.V.
	Hulsterweg 82
	5912 PL Venlo
	Netherlands
Internet:	www.qiagen.com


End of News	DGAP News Service

1104659 05.08.2020

Latest news about Qiagen N.V.

QIAGEN NV : Deutsche Bank reiterates its Buy rating	06:47am	ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	Apr. 03	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	Mar. 27	CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	Mar. 25	CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	Mar. 18	MT
Transcript : Qiagen N.V. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
QIAGEN NV : UBS reaffirms its Neutral rating	Mar. 01	ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51	Feb. 16	MT
QIAGEN NV : Berenberg reiterates its Buy rating	Feb. 16	ZD
QIAGEN NV : Deutsche Bank remains its Buy rating	Feb. 14	ZD
Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep	Feb. 08	CI
QIAGEN NV : JP Morgan reiterates its Buy rating	Feb. 08	ZD
QIAGEN NV : UBS reiterates its Neutral rating	Feb. 08	ZD
QIAGEN : In line Q4; routine business prospects remain intact	Feb. 07
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15	Feb. 07	DP
Sector Update: Health Care Stocks Mixed Premarket Wednesday	Feb. 07	MT
Transcript : Qiagen N.V., Q4 2023 Earnings Call, Feb 07, 2024	Feb. 07
QIAGEN NV : Gets a Neutral rating from UBS	Feb. 07	ZD
QIAGEN NV : Berenberg reaffirms its Buy rating	Feb. 07	ZD
QIAGEN NV : DZ Bank gives a Buy rating	Feb. 07	ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating	Feb. 07	ZD
Qiagen Q4 Adjusted Earnings, Sales Rise; 2024 Outlook Issued, Shares Slump	Feb. 06	MT
Qiagen N.V. Provides Earnings Guidance for Year 2024	Feb. 06	CI
Qiagen N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 05	CI
Qiagen N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 05	CI

Chart Qiagen N.V.

Duration

Period

More charts

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

39.67 USD

Average target price

50.72 USD

Spread / Average Target

+27.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-12.07%	8.78B
LONZA GROUP AG	+48.77%	42.16B
IQVIA HOLDINGS INC.	-0.17%	42.07B
MODERNA, INC.	+5.34%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+4.49%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-23.21%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	12.11B
MEDPACE HOLDINGS, INC.	+26.35%	11.99B
UNITED THERAPEUTICS CORPORATION	+5.92%	11.06B

Other Biotechnology & Medical Research